冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护

管文婕; 陈慧慧; 汪涛; 张晨晨; 陈延杰; 朱捷

doi:10.3969/j.issn.1006-0111.2019.04.017

冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护

doi: 10.3969/j.issn.1006-0111.2019.04.017

中国人民解放军联勤保障部队第九〇一医院药剂科, 安徽合肥 230031

基金项目: 国家科技支撑计划（2013BAI06B04）

Pharmaceutical care of antithrombotic therapy for heparin-induced thrombocytopenia after percutaneous coronary intervention

Department of Pharmacy, Hospital 901 of the Joint Logistics Support Force of PLA, Hefei 230031, China

摘要: 目的探讨临床药师在急性心肌梗死（AMI）患者经皮冠脉介入术（PCI）后发生肝素诱导的血小板减少症（heparin-induced thrombocytopenia，HIT）抗栓治疗方案制定及药学监护。方法临床药师利用急性冠脉综合征临床风险评分（GRACE）及抗血小板、抗凝治疗出血风险评分（Crusade）进行死亡风险及缺血、出血风险评估，及时调整抗栓治疗方案。出现HIT后分析血小板减少的原因及凝血功能，确定可能的相关药物因素，选择阿加曲班替代抗凝治疗，并及时监测活化部分凝血活酶时间（APTT）进行剂量调整。从药物的作用机制，不良反应，安全经济性，阐述出院带药选择华法林对患者的用药优势。结果选择阿加曲班替代抗凝治疗，维持双联抗血小板（阿司匹林+氯吡格雷）方案，患者情况控制平稳，未出现出血及血栓栓塞并发症，顺利出院。结论临床药师需要充分了解药理学及药动学变化，可协助临床发现药物治疗相关问题。同时需加强监测，以便及时调整用药方案，提高临床用药的安全性和合理性，为患者提供更好的药学服务。
- 急性心肌梗死 /
- 冠状动脉介入术 /
- 肝素 /
- 血小板减少症 /
- 抗栓 /
- 药学监护
Abstract: Objective To explore clinical pharmacists' role in antithrombotic therapy for acute myocardial infarction (AMI) inpatients with heparin-induced thrombocytopenia (HIT) after percutaneous coronary intervention (PCI). Methods Clinical pharmacists used the acute coronary syndrome clinical risk score (GRACE) and anti-platelet and anticoagulant treatment bleeding risk score (Crusade) to assess the risk of ischemia and bleeding in order to adjust the dose for antiplatelet therapy.The causes of thrombocytopenia and coagulation were evaluated.The possible medication related factors were identified for HIT patient.Argatroban was used to replace anticoagulant therapy and APTT was closely monitored in order to adjust dose in a timely manner.Warfarin was recommended for the discharged patients based on the mechanism of action,adverse reactions,safety and economics. Results No bleeding or thromboembolic complications was observed on the patient with argatroban for anticoagulant therapy and aspirin plus clopidogrel as maintenance therapy. Conclusion With good understanding in pharmacology and pharmacokinetics,clinical pharmacists can help doctors to solve the problems related to drug therapy in time.Therefore,better pharmaceutical care can be provided to patients with improved medication safety and rationality.
- acute myocardial infarction /
- percutaneous coronary intervention /
- heparin /
- thrombocytopenia /
- antithrombotic /
- pharmaceutical care

[1]	中华医学会心血管病学分会,中国心脑血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J],中华心脑血管病杂志,2015,43(5):380-386.
[2]	SALTER B S,WEINER M M,TRINH M A,et al.Heparin-induced thrombocytopenia:A comprehensive clinical review[J].J Am Coll Cardiol,2016,67(21):2519-2532.
[3]	黄震华.肝素诱发的血小板减少症的诊断和治疗进展[J].中国新药与临床杂志,2017,36(1):11-15.
[4]	BRYANT A,LOW J,AUSTIN S,et al.Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request,low incidence single centre using clinical 4T's score and particle gel immunoassay[J].Br J Haematol,2008,143(5):721-726.
[5]	HRON G,KNUTSON F,THIELE T,et al.Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF₄/heparin-antibody test[J].Ups J Med Sci,2013,118(4):279-284.
[6]	廖敏辉,李平,刘永刚,等.GRACE与CRUSADE危险评分的相关性研究[J].中国药师,2015,18(3):441-443.
[7]	American Society of Hematology.2013 Clinical Practice Guideline on the Evaluation and Management of Adults with Suspected Heparin-Induced Thrombocytopenia(HIT)[EB/OL].(2013-12-02)[2015-10-15].http://www.hematology.org/.
[8]	COSMI B.Current management of heparin-induced thrombocytopenia[J].Expert Rev Hematol,2015,8(6):837-849.
[9]	ALATRI A,ARMSTRONG A E,GREINACHER A,et al.Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective[J].Thromb Res,2012,129(4):426-433.
[10]	LEWIS B E,MATTHAI W H Jr,COHEN M,et al.Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia[J].Catheter Cardiovasc Interv,2002,57(2):177-184.
[11]	LINKINS L A,DANS A L,MOORES L K,et al.Treatment and prevention of heparin-induced thrombocytopenia:antithrombotic therapy and prevention of thrombosis,9th ed:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e495S-e530S.
[12]	汤丽萍,赵卫国.利伐沙班治疗急性肺栓塞疗效分析[J].临床肺科杂志,2014,19(10):1780-1782.
[13]	KEARON C,AKL E A,COMEROTA A J,et al.Antithrombotic therapy for VTE disease:antithrombotic therapy and prevention of thrombosis,9th ed:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e419S-e496S.
[14]	中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南[J].中华普通外科杂志,2017,32(9):807-809.
[15]	张旭光.氯吡格雷致白细胞及血小板减少[J].药物不良反应杂志,2010,12(1):54-55.
[16]	DEWILDE W J,OIRBANS T,VERHEUGT F W,et al.Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:An open-label,randomised,controlled trial[J].Lancet,2013,381(9872):1107-1115.
[17]	中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82.

[1]	王鹏, 吴宗贵, 张争艳. 活心丸（浓缩丸）联合八段锦对急性心肌梗死合并心衰介入术后预后的影响 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202308034
[2]	蔺婷婷, 曾婷婷, 田泾. 克罗恩病合并低蛋白血症患者对英夫利昔单抗失应答的用药分析与监护 . 药学实践与服务, 2023, 41(1): 59-62. doi: 10.12206/j.issn.2097-2024.202102009
[3]	刘玉兰, 刘梅, 鲁毅, 毕慧, 许桂丽. 1例急性心肌梗死合并三尖瓣修补术患者的抗栓治疗及药学监护 . 药学实践与服务, 2023, 41(12): 760-762. doi: 10.12206/j.issn.2097-2024.202204122
[4]	罗晶晶, 吴新安, 薛刚, 解正东, 叶剑波, 戎成婷. 临床药师参与1例足部损伤患者术后MRSA感染治疗的药学监护 . 药学实践与服务, 2022, 40(3): 286-288. doi: 10.12206/j.issn.1006-0111.202102004
[5]	张芸婷, 付慧, 李冬洁, 黄芳, 沈甫明. 临床药师参与1例胃癌术后腹腔感染合并蜂窝组织炎患者的药学监护 . 药学实践与服务, 2022, 40(6): 580-582. doi: 10.12206/j.issn.2097-2024.202107101
[6]	骆锦前, 陆松伟, 田泾, 虞慧华. 1例2型糖尿病伴骨质疏松患者的药学监护 . 药学实践与服务, 2022, 40(5): 473-476. doi: 10.12206/j.issn.2097-2024.202110024
[7]	卢进, 赵新才, 陈蓓蓉, 赵赟, 王婧, 霍炎. 药师对1例转移性乳腺癌术后伴癌痛患者的药学监护 . 药学实践与服务, 2021, 39(4): 359-361. doi: 10.12206/j.issn.1006-0111.202101028
[8]	刘婷, 曹忠强, 湛敏, 张洲, 吴越, 李学娟, 陈泽彬. 1例儿童细菌性脑膜炎的治疗分析与药学监护 . 药学实践与服务, 2021, 39(2): 174-177. doi: 10.12206/j.issn.1006-0111.202012022
[9]	韦春兰, 李文渊. 1例甲巯咪唑致全血细胞减少及肝损伤患者的药学监护 . 药学实践与服务, 2021, 39(1): 86-89. doi: 10.12206/j.issn.1006-0111.202004025
[10]	李星霞, 霍炎, 孙习鹏, 陈燕, 陆瑶华, 郭澄. 冠心病合并血小板减少的分析与处理策略 . 药学实践与服务, 2020, 38(1): 77-80. doi: 10.3969/j.issn.1006-0111.201906105
[11]	吴逸梅, 盛月红, 刘毅, 谢从景, 葛继芸, 黄玉凤. 1例原发性肝癌合并2型糖尿病行射频消融术治疗后并发肝脓肿的药学监护 . 药学实践与服务, 2019, 37(4): 365-369. doi: 10.3969/j.issn.1006-0111.2019.04.016
[12]	葛海沂, 丁楠. 1例Ⅱ型血小板减少症的药学监护并文献复习 . 药学实践与服务, 2019, 37(3): 279-282. doi: 10.3969/j.issn.1006-0111.2019.03.018
[13]	曹琴, 李昱柳. 1例支气管扩张合并糖尿病、痛风患者的药学监护 . 药学实践与服务, 2017, 35(2): 171-173. doi: 10.3969/j.issn.1006-0111.2017.02.019
[14]	冯瑾. 对妊娠期哮喘急性发作患者药学服务工作的体会 . 药学实践与服务, 2017, 35(2): 182-183,190. doi: 10.3969/j.issn.1006-0111.2017.02.022
[15]	张恩晖, 王海峰, 陈莉, 刘佃花, 于剑光, 蔡国君. 心肌缺血的昼夜节律性与时辰疗法 . 药学实践与服务, 2016, 34(1): 8-11,47. doi: 10.3969/j.issn.1006-0111.2016.01.003
[16]	刘丽娜, 刘晓东, 肇丽梅. 1例糖尿病合并侵袭性肺曲霉菌感染患者的药学监护 . 药学实践与服务, 2014, 32(5): 389-392. doi: 10.3969/j.issn.1006-0111.2014.05.022
[17]	侯幸赟, 焦洋, 蔡和平, 王卓. 1例肺癌合并侵袭性肺真菌感染与多种并发症患者的药学监护与分析 . 药学实践与服务, 2014, 32(2): 128-130. doi: 10.3969/j.issn.1006-0111.2014.02.014
[18]	谢华, 谢景文, 王荣, 贾正平, 徐丽婷, 马骏. 药学监护在癫痫疾病中应用的体会 . 药学实践与服务, 2007, (3): 166-168.
[19]	佟雪菲, 陈盛新, 蒯丽萍, 忻伟明. 药学人力资源现状分析与开发对策 . 药学实践与服务, 2007, (2): 114-116.
[20]	王守春, 韩丽萍, 姚小莉, 骆科. 肾移植术后的药学监护 . 药学实践与服务, 2004, (6): 365-367.

点击查看大图

计量

文章访问数: 2982
HTML全文浏览量: 451
PDF下载量: 622
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护

doi: 10.3969/j.issn.1006-0111.2019.04.017

Pharmaceutical care of antithrombotic therapy for heparin-induced thrombocytopenia after percutaneous coronary intervention

计量

冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护

doi: 10.3969/j.issn.1006-0111.2019.04.017

中国人民解放军联勤保障部队第九〇一医院药剂科, 安徽合肥 230031

English Abstract

Pharmaceutical care of antithrombotic therapy for heparin-induced thrombocytopenia after percutaneous coronary intervention

Department of Pharmacy, Hospital 901 of the Joint Logistics Support Force of PLA, Hefei 230031, China

全文HTML

目录

留言板

冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护

doi: 10.3969/j.issn.1006-0111.2019.04.017

Pharmaceutical care of antithrombotic therapy for heparin-induced thrombocytopenia after percutaneous coronary intervention

计量

出版历程

冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护

doi: 10.3969/j.issn.1006-0111.2019.04.017

中国人民解放军联勤保障部队第九〇一医院药剂科, 安徽 合肥 230031

English Abstract

Pharmaceutical care of antithrombotic therapy for heparin-induced thrombocytopenia after percutaneous coronary intervention

Department of Pharmacy, Hospital 901 of the Joint Logistics Support Force of PLA, Hefei 230031, China

全文HTML

目录

中国人民解放军联勤保障部队第九〇一医院药剂科, 安徽合肥 230031